The novel specific targeting therapies are required for osteosarcoma therapies, particularly in metastatic or relapsed osteosarcoma patients.5 Studies in recent years suggest targeting Hsp90 may be a promising strategy for the treatment of osteosarcoma. The gene discussed is HSP90AA1; the disease is osteosarcoma.